Reviewing BioNxt Solutions (OTCMKTS:BNXTF) & BioVie (NASDAQ:BIVI)

BioNxt Solutions (OTCMKTS:BNXTF) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares BioNxt Solutions and BioVie’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNxt Solutions	N/A	N/A	-815.86%
BioVie	N/A	-89.02%	-75.32%

Valuation & Earnings

This table compares BioNxt Solutions and BioVie”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNxt Solutions	$20,000.00	3,021.34	-$3.88 million	($0.04)	-13.05
BioVie	N/A	N/A	-$17.54 million	($79.10)	-0.02

BioNxt Solutions has higher revenue and earnings than BioVie. BioNxt Solutions is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioNxt Solutions has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Institutional & Insider Ownership

4.6% of BioVie shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for BioNxt Solutions and BioVie, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNxt Solutions	0	0	0	0	0.00
BioVie	1	0	0	1	2.50

Summary

BioVie beats BioNxt Solutions on 6 of the 11 factors compared between the two stocks.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

About BioVie

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.